AC Camargo Cancer Center
Welcome,         Profile    Billing    Logout  
 20 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Silva, Juliana SF
AUTO1-PY1, NCT06173518: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Recruiting
1
24
Europe, US
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
11/27
11/27
Riechelmann, Rachel SP
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
HORMONET, NCT03870399: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Completed
2
23
US, RoW
Tamoxifen
AC Camargo Cancer Center, H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
05/23
05/23
BISQUIT, NCT03870607: Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal

Recruiting
2
75
RoW
prebiotics in combination with probiotics, Symbioflor
AC Camargo Cancer Center
Anal Cancer Squamous Cell
08/23
02/24
EVENET, NCT06472388: Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Recruiting
2
100
RoW
Everolimus 5 MG
AC Camargo Cancer Center
Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Carcinoid
05/26
12/26
ACTION HIV, NCT05328765: A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

Recruiting
N/A
300
RoW
Latin American Cooperative Oncology Group
Anal Squamous Cell Carcinoma, HIV Infections
04/25
04/25
Jr, Samuel Aguiar
NCT06793137: Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Recruiting
2
100
RoW
Metronidazole
AC Camargo Cancer Center, Conselho Nacional de Desenvolvimento Científico e Tecnólogico - CNPQ
Rectal Cancer, Adenocarcinoma
10/25
04/26
DECORUM, NCT05260242: Delivering Empowering Conversations About Obstetric Regional Anesthesia for Underserved Minorities

Recruiting
N/A
100
US
Disparities Conversation
Icahn School of Medicine at Mount Sinai
Postpartum Recovery
05/25
05/25
Damian, Fernanda
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
LACOG1018, NCT03936270: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Completed
2
43
RoW
Palbociclib 125mg, Ibrance®, Letrozole 2.5mg, Femara
Latin American Cooperative Oncology Group, Pfizer
Ovarian Cancer
01/22
05/23
NCT05492123: Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting
2
112
RoW
Nivolumab 40 mg in 4 ml Injection, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy, Chemoradiation, Cisplatin-based chemoradiation
Hospital Israelita Albert Einstein, Bristol-Myers Squibb, Brava
Uterine Cervical Neoplasms
12/26
03/28
CONOR, NCT05857397: A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

Active, not recruiting
N/A
64
RoW
Observational study
Latin American Cooperative Oncology Group, GlaxoSmithKline
Ovarian Cancer
05/25
05/25
Werutsky, Gustavo
GBECAM, NCT04540692: Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Recruiting
3
444
RoW
Docetaxel or Paclitaxel, Taxotere or Taxol, Cyclophosphamide + Doxorrubicin, Citoxan + Rubidox
Latin American Cooperative Oncology Group, Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)
Breast Cancer
04/26
08/30
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
LACOG1018, NCT03936270: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Completed
2
43
RoW
Palbociclib 125mg, Ibrance®, Letrozole 2.5mg, Femara
Latin American Cooperative Oncology Group, Pfizer
Ovarian Cancer
01/22
05/23
PACIFIC BRAZIL, NCT04230408: Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers

Completed
2
48
RoW
Durvalumab, Carboplatin, Paclitaxel
Latin American Cooperative Oncology Group, AstraZeneca, Libbs Farmacêutica LTDA
Lung Neoplasms
10/24
12/24
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
LATINO Lung, NCT04227457: Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

Completed
N/A
700
RoW
Latin American Cooperative Oncology Group, Bristol-Myers Squibb
Lung Cancer
10/21
08/23
BRAVE, NCT05034393: Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Completed
N/A
308
RoW
Latin American Cooperative Oncology Group, Brazilian Breast Cancer Study Group (GBECAM)
Breast Cancer
02/23
02/23
NCT05306600: Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Recruiting
N/A
882
RoW
whole exome and whole genome sequencing analysis
Hospital Moinhos de Vento, Ministry of Health, Brazil
Breast Cancer, Prostate Cancer
12/26
12/26
Castro, Douglas G
INTRAGO-II, NCT02685605: Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

Active, not recruiting
3
314
Europe, Canada, US, RoW
Standard surgery, Intraoperative radiotherapy, IORT, Radiochemotherapy, Temozolomide
Universitätsmedizin Mannheim, Carl Zeiss Meditec AG, University of California, Los Angeles
Glioblastoma
06/24
06/26
NCT03789149: Focal Intraoperative Radiotherapy of Brain Metastases

Terminated
2
10
RoW
Intraoperative Radiotherapy, Intrabeam
AC Camargo Cancer Center, Carl Zeiss Meditec AG
Brain Metastases, Adult, Central Nervous System Metastases
06/22
06/22
Pignataro, Bruno S
NCT03512899: Comparison Between Internal Jugular Vein Versus Axillary Vein for Implantable Ports

Completed
N/A
240
RoW
Right internal jugular access., Left internal jugular access., Right axillary vein access., Left axillary vein access.
AC Camargo Cancer Center
Catheter Complications, Cancer
11/22
11/22
Nishinari, Kenji
NCT03512899: Comparison Between Internal Jugular Vein Versus Axillary Vein for Implantable Ports

Completed
N/A
240
RoW
Right internal jugular access., Left internal jugular access., Right axillary vein access., Left axillary vein access.
AC Camargo Cancer Center
Catheter Complications, Cancer
11/22
11/22
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
Zand, Behrouz
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
02/31
LEVER, NCT02397083: Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Active, not recruiting
2
102
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Mirena
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
09/26
09/26
NCT06689956: Outcomes of Low-Risk Endometrial Cancer with Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective, Multicenter, Cohort Study

Recruiting
N/A
212
Europe, Canada, US, RoW
Non-Interventional Study
Mayo Clinic
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
10/29
10/29
Geyer, Daniel
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
GOG-3069, NCT05154487: A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Recruiting
2
51
US
Alpelisib Pill, Piqray, Fulvestrant injection, Faslodex
GOG Foundation, Novartis
Endometroid Endometrial Cancer
04/25
04/26
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available
N/A
US
89Zr-DFO-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
 
 
Carvalho, Natasha
NCT05492123: Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting
2
112
RoW
Nivolumab 40 mg in 4 ml Injection, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy, Chemoradiation, Cisplatin-based chemoradiation
Hospital Israelita Albert Einstein, Bristol-Myers Squibb, Brava
Uterine Cervical Neoplasms
12/26
03/28
Moura, Lemos
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Costa, Vanelli
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Crusoe, Queiroz
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Silva, Juliana SF
AUTO1-PY1, NCT06173518: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Recruiting
1
24
Europe, US
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
11/27
11/27
Riechelmann, Rachel SP
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
HORMONET, NCT03870399: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Completed
2
23
US, RoW
Tamoxifen
AC Camargo Cancer Center, H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
05/23
05/23
BISQUIT, NCT03870607: Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal

Recruiting
2
75
RoW
prebiotics in combination with probiotics, Symbioflor
AC Camargo Cancer Center
Anal Cancer Squamous Cell
08/23
02/24
EVENET, NCT06472388: Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Recruiting
2
100
RoW
Everolimus 5 MG
AC Camargo Cancer Center
Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Carcinoid
05/26
12/26
ACTION HIV, NCT05328765: A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

Recruiting
N/A
300
RoW
Latin American Cooperative Oncology Group
Anal Squamous Cell Carcinoma, HIV Infections
04/25
04/25
Jr, Samuel Aguiar
NCT06793137: Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Recruiting
2
100
RoW
Metronidazole
AC Camargo Cancer Center, Conselho Nacional de Desenvolvimento Científico e Tecnólogico - CNPQ
Rectal Cancer, Adenocarcinoma
10/25
04/26
DECORUM, NCT05260242: Delivering Empowering Conversations About Obstetric Regional Anesthesia for Underserved Minorities

Recruiting
N/A
100
US
Disparities Conversation
Icahn School of Medicine at Mount Sinai
Postpartum Recovery
05/25
05/25
Damian, Fernanda
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
LACOG1018, NCT03936270: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Completed
2
43
RoW
Palbociclib 125mg, Ibrance®, Letrozole 2.5mg, Femara
Latin American Cooperative Oncology Group, Pfizer
Ovarian Cancer
01/22
05/23
NCT05492123: Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting
2
112
RoW
Nivolumab 40 mg in 4 ml Injection, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy, Chemoradiation, Cisplatin-based chemoradiation
Hospital Israelita Albert Einstein, Bristol-Myers Squibb, Brava
Uterine Cervical Neoplasms
12/26
03/28
CONOR, NCT05857397: A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

Active, not recruiting
N/A
64
RoW
Observational study
Latin American Cooperative Oncology Group, GlaxoSmithKline
Ovarian Cancer
05/25
05/25
Werutsky, Gustavo
GBECAM, NCT04540692: Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Recruiting
3
444
RoW
Docetaxel or Paclitaxel, Taxotere or Taxol, Cyclophosphamide + Doxorrubicin, Citoxan + Rubidox
Latin American Cooperative Oncology Group, Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)
Breast Cancer
04/26
08/30
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
LACOG1018, NCT03936270: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Completed
2
43
RoW
Palbociclib 125mg, Ibrance®, Letrozole 2.5mg, Femara
Latin American Cooperative Oncology Group, Pfizer
Ovarian Cancer
01/22
05/23
PACIFIC BRAZIL, NCT04230408: Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers

Completed
2
48
RoW
Durvalumab, Carboplatin, Paclitaxel
Latin American Cooperative Oncology Group, AstraZeneca, Libbs Farmacêutica LTDA
Lung Neoplasms
10/24
12/24
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
LATINO Lung, NCT04227457: Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

Completed
N/A
700
RoW
Latin American Cooperative Oncology Group, Bristol-Myers Squibb
Lung Cancer
10/21
08/23
BRAVE, NCT05034393: Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Completed
N/A
308
RoW
Latin American Cooperative Oncology Group, Brazilian Breast Cancer Study Group (GBECAM)
Breast Cancer
02/23
02/23
NCT05306600: Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Recruiting
N/A
882
RoW
whole exome and whole genome sequencing analysis
Hospital Moinhos de Vento, Ministry of Health, Brazil
Breast Cancer, Prostate Cancer
12/26
12/26
Castro, Douglas G
INTRAGO-II, NCT02685605: Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

Active, not recruiting
3
314
Europe, Canada, US, RoW
Standard surgery, Intraoperative radiotherapy, IORT, Radiochemotherapy, Temozolomide
Universitätsmedizin Mannheim, Carl Zeiss Meditec AG, University of California, Los Angeles
Glioblastoma
06/24
06/26
NCT03789149: Focal Intraoperative Radiotherapy of Brain Metastases

Terminated
2
10
RoW
Intraoperative Radiotherapy, Intrabeam
AC Camargo Cancer Center, Carl Zeiss Meditec AG
Brain Metastases, Adult, Central Nervous System Metastases
06/22
06/22
Pignataro, Bruno S
NCT03512899: Comparison Between Internal Jugular Vein Versus Axillary Vein for Implantable Ports

Completed
N/A
240
RoW
Right internal jugular access., Left internal jugular access., Right axillary vein access., Left axillary vein access.
AC Camargo Cancer Center
Catheter Complications, Cancer
11/22
11/22
Nishinari, Kenji
NCT03512899: Comparison Between Internal Jugular Vein Versus Axillary Vein for Implantable Ports

Completed
N/A
240
RoW
Right internal jugular access., Left internal jugular access., Right axillary vein access., Left axillary vein access.
AC Camargo Cancer Center
Catheter Complications, Cancer
11/22
11/22
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
Zand, Behrouz
ENDO-3, NCT04073706: Sentinel Node Biopsy in Endometrial Cancer

Recruiting
3
760
Europe, US, RoW
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted, TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Queensland Centre for Gynaecological Cancer, The University of Queensland
Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
01/31
02/31
LEVER, NCT02397083: Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Active, not recruiting
2
102
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Mirena
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
09/26
09/26
NCT06689956: Outcomes of Low-Risk Endometrial Cancer with Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective, Multicenter, Cohort Study

Recruiting
N/A
212
Europe, Canada, US, RoW
Non-Interventional Study
Mayo Clinic
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
10/29
10/29
Geyer, Daniel
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
GOG-3069, NCT05154487: A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Recruiting
2
51
US
Alpelisib Pill, Piqray, Fulvestrant injection, Faslodex
GOG Foundation, Novartis
Endometroid Endometrial Cancer
04/25
04/26
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available
N/A
US
89Zr-DFO-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
 
 
Carvalho, Natasha
NCT05492123: Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting
2
112
RoW
Nivolumab 40 mg in 4 ml Injection, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy, Chemoradiation, Cisplatin-based chemoradiation
Hospital Israelita Albert Einstein, Bristol-Myers Squibb, Brava
Uterine Cervical Neoplasms
12/26
03/28
Moura, Lemos
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Costa, Vanelli
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Crusoe, Queiroz
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32

Download Options